MDxHealth has signed a collaboration with a provider of anatomic pathology services, Plus Diagnostics, to co-promote its ConfirmMDx test for prostate cancer in the US.
ConfirmMDx test is a laboratory-developed test (LDT) which facilitates urologists in identifying men who may safely forego unnecessary repeat biopsies.
Under the agreement, Plus Diagnostics will build awareness of ConfirmMDx test for prostate cancer through its national network of urologists.
MDxHealth CEO Jan Groen said Plus Diagnostics is regarded for its extensive pathology expertise and premier testing services, and has built strong relationships with urologists.
"The national reach afforded by PLUS Diagnostics provides a direct channel into the urology community and will aid in meeting the growing demand for our test," Groen added.
Plus Diagnostics CEO David Pauluzzi said, "We believe this test will improve the standard of care for patients with negative prostate biopsies."